FluoroPharma Medical (OTCMKTS:FPMI) & Quipt Home Medical (NASDAQ:QIPT) Head-To-Head Comparison

FluoroPharma Medical (OTCMKTS:FPMI) and Quipt Home Medical (NASDAQ:QIPT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Valuation and Earnings

This table compares FluoroPharma Medical and Quipt Home Medical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FluoroPharma Medical	N/A	N/A	N/A	N/A	N/A
Quipt Home Medical	$245.91 million	0.46	-$6.76 million	($0.24)	-10.79

FluoroPharma Medical has higher earnings, but lower revenue than Quipt Home Medical.

Analyst Ratings

This is a breakdown of recent recommendations for FluoroPharma Medical and Quipt Home Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FluoroPharma Medical	0	0	0	0	0.00
Quipt Home Medical	1	1	1	0	2.00

Quipt Home Medical has a consensus target price of $3.15, indicating a potential upside of 21.62%. Given Quipt Home Medical’s stronger consensus rating and higher possible upside, analysts plainly believe Quipt Home Medical is more favorable than FluoroPharma Medical.

Profitability

This table compares FluoroPharma Medical and Quipt Home Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
FluoroPharma Medical	N/A	N/A	N/A
Quipt Home Medical	-4.30%	-9.78%	-4.23%

Institutional & Insider Ownership

42.9% of Quipt Home Medical shares are owned by institutional investors. 36.9% of FluoroPharma Medical shares are owned by company insiders. Comparatively, 13.4% of Quipt Home Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Quipt Home Medical beats FluoroPharma Medical on 5 of the 9 factors compared between the two stocks.

About FluoroPharma Medical

FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.

About Quipt Home Medical

Quipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment. It offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep apnea, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. is headquartered in Wilder, Kentucky.